Literature DB >> 15179453

The potential of bacterial fatty acid biosynthetic enzymes as a source of novel antibacterial agents.

David J Payne1.   

Abstract

Bacteria can produce new progeny in only 20 minutes (500,000 times faster than humans), enabling them to rapidly mutate and evolve ingenious methods to outwit just about all of the currently available antibiotics. These mechanisms can then disseminate rapidly through bacterial populations via transmissible pieces of DNA such as transposons, integrons and plasmids. This leads to resistance mechanisms becoming geographically dispersed and has resulted in the overall decrease in the susceptibility of microorganisms to antibiotics that used to be highly efficacious. There is an obvious need for new antibiotics that kill bacteria via novel mechanisms not previously exploited by existing agents; this will provide new generations of antibiotics unlikely to be compromised by preexisting resistance mechanisms. The fatty acid biosynthetic pathway is an essential metabolic process in bacteria and presents several novel targets for antibiotic development. (c) 2004 Prous Science. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15179453     DOI: 10.1358/dnp.2004.17.3.829016

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN: 0214-0934


  5 in total

1.  Molecular modeling studies of Fatty acyl-CoA synthetase (FadD13) from Mycobacterium tuberculosis--a potential target for the development of antitubercular drugs.

Authors:  Nidhi Jatana; Sarvesh Jangid; Garima Khare; Anil K Tyagi; Narayanan Latha
Journal:  J Mol Model       Date:  2010-05-08       Impact factor: 1.810

2.  Crystallization and preliminary X-ray crystallographic analysis of enoyl-ACP reductase III (FabL) from Bacillus subtilis.

Authors:  Kook-Han Kim; Joon Kyu Park; Byung Hak Ha; Jin Ho Moon; Eunice EunKyeong Kim
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-02-28

3.  Resin-based investigation of acyl carrier protein interaction networks in Escherichia coli.

Authors:  Michael Rothmann; Sherry Niessen; Robert W Haushalter; Benjamin F Cravatt; Michael D Burkart
Journal:  Bioorg Med Chem       Date:  2011-10-31       Impact factor: 3.641

4.  A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore.

Authors:  J Richard Miller; Steve Dunham; Igor Mochalkin; Craig Banotai; Matthew Bowman; Susan Buist; Bill Dunkle; Debra Hanna; H James Harwood; Michael D Huband; Alla Karnovsky; Michael Kuhn; Chris Limberakis; Jia Y Liu; Shawn Mehrens; W Thomas Mueller; Lakshmi Narasimhan; Adam Ogden; Jeff Ohren; J V N Vara Prasad; John A Shelly; Laura Skerlos; Mark Sulavik; V Hayden Thomas; Steve VanderRoest; LiAnn Wang; Zhigang Wang; Amy Whitton; Tong Zhu; C Kendall Stover
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-22       Impact factor: 11.205

5.  Structure-assisted discovery of an aminothiazole derivative as a lead molecule for inhibition of bacterial fatty-acid synthesis.

Authors:  Günter Pappenberger; Tanja Schulz-Gasch; Eric Kusznir; Francis Müller; Michael Hennig
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2007-11-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.